Elaine Lam, MD

Professional Titles

• Cancer Research Medical Director, UCHealth Cancer Center at Highlands Ranch Hospital
• Medical Director, Cancer Center Infusion Center, University of Colorado Hospital
• Director of the Medical Oncology Kidney Cancer Program, University of Colorado Cancer Center, UCHealth Anschutz Medical Campus
• Professor, Department of Medicine, Division of Medical Oncology

Recognitions

• Fellow of the American College of Physicians, American College of Physicians (2018)

Research Interests

My research is focused on the clinical development of novel therapeutics for patients with prostate, kidney, bladder/urothelial, and testicular cancers. I serve as the Cancer Research Medical Director at UCHealth Cancer Center at Highlands Ranch Hospital. I direct the Medical Oncology Kidney Cancer Program at the University of Colorado Cancer Center and am a voting member of the National Comprehensive Cancer Network Kidney Cancer Panel.

Publications

• Lam ET, Ringel MD, Kloos RT, Prior T, Knopp MV, Vasko V, Liang J, Sammet S, Hall NC, Wakely PE, Motoyasu S, Snyder P, Wei L, Arbogast D, Collamore M, Wright JJ, Moley J, Villalona-Calero MA, and Shah MH. A phase II clinical trial of the multi-kinase inhibitor, sorafenib, in metastatic medullary thyroid cancer. J Clin Oncol, 2010;28(14):2323-30. Epub 2010 Apr 5, doi:10.1200/JCO.2009.25.0068. PMID: 20368568.
• Lam ET, Au JS, Otterson GA, Guillaume-Wientjes M, Chen L, Shen T, Wei Y, Young D, Murgo AJ, Jenson RR, Grever M, and Villalona-Calero MA. A phase I trial of non-cytotoxic suramin as modulator of docetaxel and gemcitabine therapy in previously treated non-small cell lung cancer. Cancer Chemother Pharmacol 2010;66(6):1019-29. Epub 2010 Jan 28, doi:10.1007/s00280-010-1252-x. PMID: 20107799.
• Lam ET, O’Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt G, and Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther 2008;7(12):3685-94. PMID: 19074845.
• Lam ET, Goel S, Schaaf L, McCracken B, Desai K, Cropp GF, Zhou Y, Johnson RG, Hannah AI, Mani S, and Villalona-Calero MA. Phase I dose escalation trial of the novel epothilone KOS-1584 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011 Aug 27, doi: 10.1007/s00280-011-1724-7. [Epub ahead of print]. PMID: 21874318.
• Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase 1 study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Feb 3. [Epub ahead of print] PubMed PMID: 24493827
• Lam ET, Kessler ER, Flaig TW, La Rosa FG. Collision renal cell papillary and medullary carcinoma in a 66-year-old man. Oncology (Williston Park). 2013 Sep;27(9):893, 896, 898. PubMed PMID: 24282987
• Lam ET, Glodé LM. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. PubMed PMID: 24188258
• Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glode LM, Flaig TW. A Rare Case of Metastatic Renal Epithelioid Angiomyolipoma. Oncology 2011 Aug;25(9):832-8. PMID: 21936445.
• Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May;49(5):303-15. PubMed PMID: 23724410
• Lam ET, Kloos RT, Ringel MD, and Shah MH. Reply to A Machens et al. Published online before print August 16, 2010, doi: 10.1200/JCO.2010.30.0426 JCO October 1, 2010 vol. 28 no. 28 e535-e536. PMID: 20713875.
• Lam ET and Glode LM. Management of locally advanced prostate cancer. In Urological Oncology, 2nd Edition 2012, edited by Drs. Vinod Nargund, Derek Raghaven & Howard M. Sandler. Under review.
• Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct;48(10):633-44. PubMed PMID: 23110259
• Lam ET, Otterson GA, Donthireddy KR, Thurmond J, Hade EM, Coffey MC, and Villalona-Calero MA. Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have kras or EGFR activated tumors. In: J Clin Oncol 28:15s, 2010 (suppl; abstr TPS292)
• Lam ET, Mortazavi A, Phillips GS, Sharp D, Zynger D. Viability of glomeruli and proximity to tumor in partial nephrectomy specimens for renal cell carcinoma. In: Modern Pathology 2011 Feb;(24):205A.
• Lam ET, Lesinski G, Mortazavi A, Kendra KL, Carson WE, Bhinder A, Tahiri S, Liersemann R, Clinton SK, Olencki T, Monk JP. Phase I study of bolus high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma. In: J Clin Oncol 29: 2011 (suppl 7; abstr 337)
• Lam ET, Glodé LM. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer. Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. PubMed PMID: 24188258
• Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. PubMed PMID: 24493827
• Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T. Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. In: J Clin Oncol 29: 2011 (suppl; abstr e15079)
• Villalona-Calero, MA, Lam ET, Otterson G, Zhao W, Donthireddy K, Thurmond J, Hade E, Pennington J, Mettinger K, Coffey M. Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. In: Proceedings of the 14th World Conference on Lung Cancer: Journal of Thoracic Oncology 2011 (abstr MO 15.08)
• Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE 3rd, Tahiri S, Bhinder A, Clinton SK, Olencki T. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma. J Immunother. 2014 Apr;37(3):180-6. PubMed PMID: 24598448
• Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O’Bryant CL, Rmanathan RK, Weiss GJ, Chadha M, Fulk M, Yarian R, Oey A, Ding HT, Culp P, Parli T, Tsao C, Singhal A, Obrocea M, Holen KD, Von Hoff D. A Phase I Study Of Enavatuzumab (PDL192, ABT-361), A First-In-Class Human Monoclonal Antibody Targeting The TWEAK (Tumor Necrosis Factor-Like Inducer Of Apoptosis) Receptor, In Patients (Pts) With Advanced Solid Tumors. In: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, California. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl): Abstract nr C18.
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer MA, Kumar R, Natiomal compresensive cancer networks. Kidney cancer, version 2.2014. J Natl Compr Canc Netw. 2014 Feb;12(2):175-82. PubMed PMID: 24586079
• Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Gao D, Flaig TW, Lewis K, Poust J, Monk P, Jarkowski A, Sendilnathan A, Bolden M, Kuzel TM, Olencki T. Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma. J Immunother. 2014 Sep;37(7):360-5. PubMed PMID: 25075565
• Kidney Cancer: An Oncologist Witnesses the Resilience of the Human Spirit Published on line on www.bettermedicine.com in October 2011
• Lam ET, O’Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt G, and Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther 2008;7(12):3685-94. PMID: 19074845.
• Lam ET, Au JS, Otterson GA, Guillaume-Wientjes M, Chen L, Shen T, Wei Y, Young D, Murgo AJ, Jenson RR, Grever M, and Villalona-Calero MA. A phase I trial of non-cytotoxic suramin as modulator of docetaxel and gemcitabine therapy in previously treated non-small cell lung cancer. Cancer Chemother Pharmacol 2010;66(6):1019-29. Epub 2010 Jan 28, doi:10.1007/s00280-010-1252-x. PMID: 20107799.
• Lam ET, Ringel MD, Kloos RT, Prior T, Knopp MV, Vasko V, Liang J, Sammet S, Hall NC, Wakely PE, Motoyasu S, Snyder P, Wei L, Arbogast D, Collamore M, Wright JJ, Moley J, Villalona-Calero MA, and Shah MH. A phase II clinical trial of the multi-kinase inhibitor, sorafenib, in metastatic medullary thyroid cancer. J Clin Oncol, 2010;28(14):2323-30. Epub 2010 Apr 5, doi:10.1200/JCO.2009.25.0068. PMID: 20368568.
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb;13(2):151-9. PubMed PMID: 25691606
• Lam ET, Goel S, Schaaf L, McCracken B, Desai K, Cropp GF, Zhou Y, Johnson RG, Hannah AI, Mani S, and Villalona-Calero MA. Phase I dose escalation trial of the novel epothilone KOS-1584 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011 Aug 27, doi: 10.1007/s00280-011-1724-7. [Epub ahead of print]. PMID: 21874318.
• Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glode LM, Flaig TW. A Rare Case of Metastatic Renal Epithelioid Angiomyolipoma. Oncology 2011 Aug;25(9):832-8. PMID: 21936445.
• Lam ET, Kloos RT, Ringel MD, and Shah MH. Reply to A Machens et al. Published online before print August 16, 2010, doi: 10.1200/JCO.2010.30.0426 JCO October 1, 2010 vol. 28 no. 28 e535-e536. PMID: 20713875.
• Lam ET and Flaig TW. Celecoxib trampled in STAMPEDE trial (commentary on James et al. "Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial"). Nat Rev Urol. 2012 May 29;9(7):358-60. doi: 10.1038/nrurol.2012.112. PMID: 22641162.
• Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct;48(10):633-44. doi: 10.1358/dot.2012.48.10.1860768. PMID: 23110259.
• Lam ET and Glode LM. Management of locally advanced prostate cancer. In Urological Oncology, 2nd Edition 2012, edited by Drs. Vinod Nargund, Derek Raghaven & Howard M. Sandler. In submission.
• Lam ET, Otterson GA, Donthireddy KR, Thurmond J, Hade EM, Coffey MC, and Villalona-Calero MA. Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have kras or EGFR activated tumors. In: J Clin Oncol 28:15s, 2010 (suppl; abstr TPS292)
• Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015 Jun;33(3):691-9. PubMed PMID: 25895965
• Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10;33(14):1601-8. PubMed PMID: 25847934
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun;13(6):772-99. PubMed PMID: 26085393
• Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e589-96. PubMed PMID: 26142027
• Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, Sharp DS, Zynger DL. Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens. Urology. 2016 Jan;87:114-9. PubMed PMID: 26505834
• Lam ET, Mortazavi A, Phillips GS, Sharp D, Zynger D. Viability of glomeruli and proximity to tumor in partial nephrectomy specimens for renal cell carcinoma. In: Modern Pathology 2011 Feb;(24):205A.
• Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer. 2015 Dec 28. [Epub ahead of print] PubMed PMID: 26709987
• Lam ET, Lesinski G, Mortazavi A, Kendra KL, Carson WE, Bhinder A, Tahiri S, Liersemann R, Clinton SK, Olencki T, Monk JP. Phase I study of bolus high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma. In: J Clin Oncol 29: 2011 (suppl 7; abstr 337)
• Lam ET, Wong MK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T. Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. In: J Clin Oncol 29: 2011 (suppl; abstr e15079)
• Villalona-Calero, MA, Lam ET, Otterson G, Zhao W, Donthireddy K, Thurmond J, Hade E, Pennington J, Mettinger K, Coffey M. Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. In: Proceedings of the 14th World Conference on Lung Cancer: Journal of Thoracic Oncology 2011 (abstr MO 15.08)
• Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O’Bryant CL, Rmanathan RK, Weiss GJ, Chadha M, Fulk M, Yarian R, Oey A, Ding HT, Culp P, Parli T, Tsao C, Singhal A, Obrocea M, Holen KD, Von Hoff D. A Phase I Study Of Enavatuzumab (PDL192, ABT-361), A First-In-Class Human Monoclonal Antibody Targeting The TWEAK (Tumor Necrosis Factor-Like Inducer Of Apoptosis) Receptor, In Patients (Pts) With Advanced Solid Tumors. In: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, California. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl): Abstract nr C18.
• Khemees TA, Lam ET, Mortazavi A, Phillips G, Shabsigh A, Sharp DS, Zynger DL. Viability of glomeruli adjacent to tumor in partial nephrectomy specimens for renal cell carcinoma. J of Urology, Vol. 187, Issue 4, Supplement, Pages e448-e449.
• Bowles DW, Diamond JR, Lam ET, Messersmith WA, Weekes CD, Leong S, Gore L, Lieu CH, Freas E, Ren C, Wilhelm F, Eckhardt SG, Jimeno A. Phase 1 study of oral rigosertib in patients with advanced solid tumors. J Clin Oncol 30, 2012 (suppl; abstr 3017).
• O’Donnell PH, Goldman JW, Gordon MS, Shih K, Choi YJ, Lu D, Kabbarah O, Ho W, Rooney I, Lam ET. A Phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients (pts) with advanced solid tumors. Poster presentation at EORTC-NCI-AACR Annual Meeting 2012, Nov 6-9, Dublin, Ireland.
• Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28;10:218. PubMed PMID: 26510665
• Kessler ER, Su LJ, Yang XP, Lu X, Morales D, Anduha M, Chronister N, Wacker M, Flaig TW, Glode LM, Lam ET. Phase II trial of acai juice product in biochemically recurrent prostate cancer. Poster presentation at ASCO Genitourinary Cancers Symposium 2013, Feb 14-16, Orlando, FL
• Bourlon MT, Meneses-Medina M, Vázquez-Manjarrez S, Bustamante-Romero FM, Gallegos-Garza AC, Lam ET. A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma. Oncology (Williston Park). 2015 Nov;29(11):880-6. PubMed PMID: 26573066
• 12. Ma WW, Lam ET, Dy GK, Diamond J, Zhao Y, Bui L, Fetterly G, Abramowitz G, Harning R, Pencheva P, Bhowmik S, Divekar G, DiRaddo AM, Eckhardt SG, Adjei A, Jimeno A. A pharmacokinetic and dose escalating study of paclitaxel injection concentrate for Nano-Dispersion (PICN) alone and with carboplatin in advanced solid tumor patients. In submission for presentation at ASCO Annual Meeting 2013, May 31- Jun 4, Chicago, IL.
• Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 Dec;29(12). PubMed PMID: 26676900
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb;13(2):151-9. PubMed PMID: 25691606
• Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 Dec;5(12):3386-3393. PubMed PMID: 27758076
• Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015 Jun;33(3):691-9. PubMed PMID: 25895965
• Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET. Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol. 2017 Mar 1;28(3):668. PubMed PMID: 28426121
• Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun;35(6):438-446. PubMed PMID: 28214281
• Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Jun;15(6):804-834. PubMed PMID: 28596261
• Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10;33(14):1601-8. PubMed PMID: 25847934
• Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2017 Dec 19;:JCO2017742627. [Epub ahead of print] PubMed PMID: 29257710
• Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 Jan;17(1):215-221. PubMed PMID: 29054986
• Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun;13(6):772-99. PubMed PMID: 26085393
• Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 Jan;17(1):215-221. PubMed PMID: 29054986
• Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e589-96. PubMed PMID: 26142027
• Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res. 2018;7:307. PubMed PMID: 29568504
• Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, Sharp DS, Zynger DL. Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens. Urology. 2016 Jan;87:114-9. PubMed PMID: 26505834
• Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther. 2018 Dec;17(4):1103-1108. PubMed PMID: 30289005
• Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT). Radiat Oncol. 2015 Oct 28;10:218. PubMed PMID: 26510665
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13. PubMed PMID: 26406148
• Bourlon MT, Meneses-Medina M, Vázquez-Manjarrez S, Bustamante-Romero FM, Gallegos-Garza AC, Lam ET. A Patient With Newly Diagnosed Metastatic Type 2 Papillary Renal Cell Carcinoma. Oncology (Williston Park). 2015 Nov;29(11):880-6. PubMed PMID: 26573066
• Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 Apr;20(4):581-590. PubMed PMID: 30827746
• Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer. 2016 Mar 15;122(6):875-83. PubMed PMID: 26709987
• Lam ET, Flaig TW. Upfront Chemotherapy for Metastatic Prostate Cancer. Oncology (Williston Park). 2015 Dec;29(12). PubMed PMID: 26676900
• Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 Sep 1;34(25):3005-13. PubMed PMID: 27400947
• Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med. 2016 Dec;5(12):3386-3393. PubMed PMID: 27758076
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115. PubMed PMID: 30779531
• Gupta A, Pugh TJ, Lam E, Sheridan AD, Nath S. The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer. Oncology (Williston Park). 2019 May 14;33(5):187-91. PubMed PMID: 31095719
• Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019 Jun 15;393(10189):2404-2415. PubMed PMID: 31079938
• Washino S, Rider LC, Romero L, Jillson LK, Affandi T, Ohm AM, Lam ET, Reyland ME, Costello JC, Cramer SD. Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination. Mol Cancer Res. 2019 Oct;17(10):1985-1998. PubMed PMID: 31300540
• Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. PubMed PMID: 31693980
• Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 Sep;18(9):1160-1170. PubMed PMID: 32886895
• Shay R, Nicklawsky A, Gao D, Lam ET. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 Aug;19(4):370-370.e7. PubMed PMID: 33674224
• Amirault M, Choo S, Waxweiler T, Weisdack SD, Breaker K, Flaig TW, Lam ET. Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. Cancer Treat Res Commun. 2021;27:100367. PubMed PMID: 33839514
• Corona-Rodarte E, Olivas-Martínez A, Remolina-Bonilla YA, Domínguez-Cherit JG, Lam ET, Bourlon MT. Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma. Int J Dermatol. 2021 Oct;60(10):1242-1247. PubMed PMID: 33871070
• Duarte C, Gilbert DM, Sheridan AD, La Rosa FG, McCarter M, Cost NG, Emmons S, Lam ET. Spontaneous regression of an extragonadal seminomatous germ cell tumor. Cancer Treat Res Commun. 2021;28:100383. PubMed PMID: 33992855
• Green DB, La Rosa FG, Craig PG, Khani F, Lam ET. Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors. Korean J Radiol. 2021 Oct;22(10):1650-1657. PubMed PMID: 34402242
• Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 1;7(12):1815-1823. PubMed PMID: 34673916
• Bilen MA, Rini BI, Voss MH, Larkin J, Haanen JBAG, Albiges L, Pagliaro LC, Voog EG, Lam ET, Kislov N, McGregor BA, Lalani AA, Huang B, Pietro AD, Krulewicz S, Robbins PB, Choueiri TK. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin Cancer Res. 2021 Nov 17. [Epub ahead of print] PubMed PMID: 34789480
• Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Rosenberg A, Sborov D, Valent J, Berardi R, Kumar R. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jan;20(1):67-81. PubMed PMID: 34991070
• Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol. 2021 Jun;87(6):779-788. PubMed PMID: 33634324
• McGregor BA, Xie W, Adib E, Stadler WM, Zakharia Y, Alva A, Michaelson MD, Gupta S, Lam ET, Farah S, Nassar AH, Wei XX, Kilbridge KL, Harshman L, Signoretti S, Sholl L, Kwiatkowski DJ, McKay RR, Choueiri TK. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 Feb;6:e2100448. PubMed PMID: 35171658
• Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, Vangala S, Gutierrez AA, Haas NB. ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. Oncologist. 2022 Jun 8;27(6):453-461. PubMed PMID: 35373299
• Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol. 2022 Jul;90(1):7-17. PubMed PMID: 35731258
• Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2022 Nov 19. [Epub ahead of print] PubMed PMID: 36402814
• Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):188-193. PubMed PMID: 36402814
• Santoni M, Molina-Cerrillo J, Santoni G, Lam ET, Massari F, Mollica V, Mazzaschi G, Rapoport BL, Grande E, Buti S. Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences. Cancers (Basel). 2023 Jan 7;15(2). PubMed PMID: 36672355
• Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer. 2023 Aug;21(4):483-490. PubMed PMID: 37193610
• Gilbert D, Hu J, Medina T, Kessler ER, Lam ET. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors. Hum Vaccin Immunother. 2023 Dec 31;19(1):2207438. PubMed PMID: 37157982
• Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. PubMed PMID: 37248424
• Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. Oncologist. 2023 Jun 27. [Epub ahead of print] PubMed PMID: 37368355
• Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 Jun;3(6):1004-1012. PubMed PMID: 37377613
• Duarte C, Hu J, Beuselinck B, Panian J, Weise N, Dizman N, Collier KA, Rathi N, Li H, Elias R, Martinez-Chanza N, Rose TL, Harshman LC, Gopalakrishnan D, Vaishampayan U, Zakharia Y, Narayan V, Carneiro BA, Mega A, Singla N, Meguid C, George S, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay RR, Lam ET. Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study. EClinicalMedicine. 2023 Jun;60:102018. PubMed PMID: 37304495
• Hakimi K, Saidian A, Panian J, Barata P, Berg S, Chang SL, Saliby RM, Dzimitrowicz H, Emamekhoo H, Gross E, Kilari D, Lam E, Nguyen M, Meagher M, Wang L, Rauterkus GP, D'Andrea V, Yim K, Psutka S, Thapa B, Weise N, Zhang T, McKay RR, Derweesh IH. Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis. Clin Genitourin Cancer. 2023 Dec;21(6):694-702. PubMed PMID: 37558529
• Bourlon MT, Remolina-Bonilla YA, Acosta-Medina AA, Saldivar-Oviedo BI, Perez-Silva A, Martinez-Ibarra N, Castro-Alonso FJ, Martín-Aguilar AE, Rivera-Rivera S, Mota-Rivero F, Pérez-Pérez P, Díaz-Alvarado MG, Ruiz-Morales JM, Campos-Gómez S, Martinez-Cannon BA, Lam ET, Sobrevilla-Moreno N. Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma. Front Oncol. 2023;13:1229016. PubMed PMID: 38044992
• Wiesen B, Atwell M, Leavitt C, Clark N, Kessler E, Lam E, Flaig T, Kukreja J, Kim S, Maroni P, Cost NG. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2023 Dec 21;:OP2300580. [Epub ahead of print] PubMed PMID: 38127812
• Santoni M, Massari F, Takeshita H, Tapia JC, Dionese M, Pichler R, Rizzo M, Lam ET, Grande E, Kemp R, Molina-Cerrillo J, Calabrò F, Tural D, Küronya Z, Kucharz J, Fiala O, Seront E, Kopp RM, Abahssain H, Kopecky J, Martignetti A, Kanesvaran R, Zakopoulou R, Ansari J, Landmesser J, Mollica V, Porta C, Bellmunt J, Salah S, Santini D. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study. Clin Exp Med. 2023 Dec;23(8):5413-5422. PubMed PMID: 37917218

Professional Memberships

• American Medical Association, Member
• American College of Physicians (ACP), Fellow
• American Society of Clinical Oncology, Member
• University of Colorado Cancer Center, Developmental Therapeutics Program, Member

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

University of Colorado Cancer Center - Anschutz Medical Campus
1665 Aurora Ct
Aurora, CO 80045
720-848-0300

UCHealth Lone Tree Medical Center
9548 Park Meadows Drive
Lone Tree, CO 80124
720-848-2200

UCHealth Tony Grampsas Urologic Cancer Care Clinic - Anschutz Medical Campus
1665 Aurora Ct
1st Floor
Aurora, CO 80045
720-848-0170

CU Medicine Medical Oncology - Highlands Ranch Specialty Care Center
1500 Park Central Drive
Suite 101
Highlands Ranch, CO 80129
720-516-1100

Hospital Affiliation

• University of Colorado Hospital
• UCHealth Highlands Ranch Hospital

Center Affiliations

• University of Colorado Cancer Center

Specialty Information

Specialties

• Internal Medicine, Board Certification (2006, 2016)
• Medical Oncology, Board Certification (2010, 2020)

Conditions & Treatments

• Cancers - Prostate Cancer
• Cancers - Testicular Cancer
• Cancers - Kidney Cancer
• Cancers - Bladder Cancer
• Cancers